OPKO Health (OPK) Misses Q4 EPS by 9c, Revenue Beats

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ORCL
2. AVGO
3. BA
4. CDNS
5. ANT
6. META
7. HOOD
8. SPY
9. STX
10. INTC

Go back to OPKO Health (OPK) Misses Q4 EPS by 9c, Revenue Beats

OPKO Health Reports 2021 Fourth Quarter Business Highlights and Financial Results

February 24, 2022 4:05 PM EST

MIAMI, Feb. 24, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended December 31, 2021.

Business Highlights

Business highlights for the fourth quarter of 2021 and subsequent weeks include the following:

NGENLA® (somatrogon) injection granted regulatory approvals in Europe, Japan, Australia and Canada for pediatric growth hormone deficiency. NGENLA® is a once-weekly, long-acting recombinant human growth hormone for the long-term treatment of growth... More